In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog

Rebecca A. Owens, Ryan J. Hansen, Steven D. Kahl, Chen Zhang, Xiaoping Ruan, Anja Koester, Shun Li, Hui-Rong Qian, Mark W. Farmen, M. Dodson Michael, Julie S. Moyers, Gordon B. Cutler, Jr., Andrew Vick, and John M. Beals

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana

Received November 30, 2015; accepted March 22, 2016

ABSTRACT
The aim of this research was to characterize the in vivo and in vitro properties of basal insulin peglispro (BIL), a new basal insulin, wherein insulin lispro was derivatized through the covalent and site-specific attachment of a 20-kDa polyethylene-glycol (PEG; specifically, methoxy-terminated) moiety to lysine B28. Addition of the PEG moiety increased the hydrodynamic size of the insulin lispro molecule. Studies show there is a prolonged duration of action and a reduction in clearance. Given the different physical properties of BIL, it was also important to assess the metabolic and mitogenic activity of the molecule. Streptozotocin (STZ)-treated diabetic rats were used to study the pharmacokinetic and pharmacodynamic characteristics of BIL. Binding affinity and functional characterization of BIL were compared with those of several therapeutic insulins, insulin AspB10, and insulin-like growth factor 1 (IGF-1). BIL exhibited a markedly longer time to maximum concentration after subcutaneous injection, a greater area under the concentration-time curve, and a longer duration of action in the STZ-treated diabetic rat than insulin lispro. BIL exhibited reduced binding affinity and functional potency as compared with insulin lispro and demonstrated greater selectivity for the human insulin receptor (hIR) as compared with the human insulin-like growth factor 1 receptor. Furthermore, BIL showed a more rapid rate of dephosphorylation following maximal hIR stimulation, and reduced mitogenic potential in an IGF-1 receptor–dominant cellular model. PEGylation of insulin lispro with a 20-kDa PEG moiety at lysine B28 alters the absorption, clearance, distribution, and activity profile receptor, but does not alter its selectivity and full agonist receptor properties.

Introduction

The normal human pancreas secretes approximately 1 unit of insulin (0.035 mg) per hour to maintain basal glycemic control in the fasting state (Waldhausl et al., 1979). Adequate basal insulin is critical because it regulates hepatic glucose output, which is essential for proper maintenance of glucose homeostasis during the diurnal cycle. When insulin is released from the pancreas, it flows first to the liver via the portal vein, where insulin receptor–mediated clearance results in approximately 50% reduction of the levels exiting the liver (Herring et al., 2014); therefore, under normal physiology, the exposure level of endogenously secreted insulin is greater in the liver than at peripheral tissues (Waldhausl et al., 1979). When therapeutic doses of insulin are administered subcutaneously, peripheral tissues are exposed to the exogenously delivered insulin before extraction by the liver, which results in equal exposure of insulin in the liver and periphery (Hordern et al., 2005). This loss of the normal insulin gradient with current insulin therapeutics results in relative peripheral hyperinsulinemia with underinsulinization of the liver (Logtenberg et al., 2009).

Over the past 75 years, differing strategies have provided insulin therapies for patients with diabetes. The design of the early basal insulin analogs was directed primarily at modifying the patterns of absorption from a depot after an s.c. injection. The suspension-based basal insulin formulations—for example, neutral protamine Hagedorn (NPH) insulin, protamine zinc insulin, lente, and ultralente—were designed to delay the release of insulin from the injection site and thus prolong glucose-lowering activity (Krayenbühl and Rosenberg, 1946; Halls-Moller, 1956; Hagedorn et al., 1984). However, these formulations were suboptimal as once-daily basal insulin replacements due to: 1) incomplete and inadequate duration of action (less than 24-hour coverage) (Bolli et al., 2011), 2) variable absorption, and 3) pronounced variation in the pharmacodynamic (PD) peaks.

Novel insulin analogs have been developed that improved basal characteristics. First-generation insulin analogs, such as...
as insulin glargine (Wang et al., 2003) and insulin detemir (Havelund et al., 2004), extended the duration of action sufficiently to permit once-daily dosing for many patients (Lepore et al., 2000; Porcellati et al., 2007). However, the in vivo properties of both of these modified insulins still possessed limitations. The intrapatient PD variability for insulin glargine was better than that of NPH, but still remained high, and the duration of action for insulin detemir was generally considered less than 24 hours (Lepore et al., 2000; Porcellati et al., 2007; Vora and Heise, 2013). Consequently, new generations of basal insulin analogs are in development, with the goals of prolonging the duration of action and reducing intrapatient variability.

Insulin degludec (Jonassen et al., 2012), which contains a fatty-acid modification similar to that in insulin detemir, offers both reduced intrapatient variability (Heise et al., 2011) and a longer duration of action (Heise et al., 2011) than that of insulin glargine. The noncovalent association of insulin detemir and insulin degludec with serum albumin alters the activity, disposition, and clearance of these insulins as compared with other exogenously administered insulins (Rakbin et al., 1970; Ferrannini et al., 1983; Henriksten et al., 1987). However, the low-affinity agonism of insulin detemir and insulin degludec, coupled with albumin binding (Nishimura et al., 2010; Sorensen et al., 2010), necessitates higher plasma concentrations to achieve in vivo potency comparable to that of NPH (Brunner et al., 2000). Insulin detemir has shown a slightly increased hepatic versus peripheral activity (Hordern et al., 2005); however, no data on hepato-preferential activity with insulin degludec have been reported.

Basal insulin peglispro (BIL), an insulin lispro molecule having a single 20-kDa polyethylene-glycol (PEG) moiety covalently attached to the epsilon amine of lysine at position B$_{28}$ of the insulin lispro molecule, represents a new generation of basal insulin (Hansen et al., 2012b). BIL showed lower intrapatient PD variability, a lower PD peak profile at steady state, and an increased duration of action compared to insulin glargine (Bergental et al., 2014; Sinha et al., 2014a,b). Recent analysis has shown that the addition of the 20-kDa PEG moiety makes the hydrodynamic diameter of BIL similar to that observed for human serum albumin, a molecule with a molecular weight too large to be readily cleared by the kidneys (Hansen et al., 2012b). Recent studies demonstrated that BIL has limited diffusion across the continuous capillary endothelial cells of the periphery, decreased renal clearance, and displays a hepato-preferential action (Henry et al., 2014; Moore et al., 2014). This hepato-preferential activity may account, in part, for the weight loss observed in patients previously treated with alternative insulin therapies that create hyperinsulinemia in the periphery (Jacob et al., 2014).

This report describes the pharmacokinetic (PK) and PD characteristics of BIL and compares them with those of insulin lispro in the insulin-deficient streptozotocin (STZ)-treated diabetic rat model. In addition, an assessment of the in vitro pharmacological properties of BIL was compared with the properties of insulin-like growth factor 1 (IGF-1), biosynthetic human insulin (BHI), and other insulin analogs (insulin lispro, insulin AspB10, insulin glargine, and insulin detemir).

## Materials and Methods

**Materials.** BIL, BHI, insulin lispro, and insulin AspB10 were prepared at Eli Lilly and Company (Indianapolis, IN). BHI, insulin lispro, and BIL were prepared at 100 IU containing water, 16 mg of glycine, 1.88 mg of dibasic sodium phosphate, 3.15 mg of m-cresol, and 0.0197 mg of zinc ion per 1 ml of pH 7.4 solution and stored at 4°C. IGF-1 (PeproTech, Rocky Hill, NJ) and AspB10 were prepared at 1 mg/ml in phosphate-buffered saline (PBS), pH 7.4. Insulin detemir (Levetir; Novo Nordisk A/S, Copenhagen, Denmark; Novo Nordisk, 2013) and insulin glargine (Lantus; Sanofi-Aventis, Paris, France; Sanofi-Aventis, 2013) were 100 IU/ml in their commercial formulation.

**PK and PD Studies in STZ-Treated Diabetic Rats.** In vivo data represent data obtained across multiple studies in male Sprague-Dawley rats. Rats were rendered diabetic by a single intravenous injection of 40–45 mg/kg STZ (Sigma-Aldrich, St. Louis, MO or Teva Parenteral Medicines, Irvine, CA). After approximately 3 days, fed blood glucose levels were determined, and rats were randomized by body weight and blood glucose. All rats had predose blood glucose levels $>345$ mg/dl. Compounds or placebos used in the studies were administered subcutaneously, with animals receiving water and food ad libitum. Blood samples were collected for measurement of immunosorbent assay and blood glucose by glucometer or Hitachi Clinical Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN).

**hIR Phosphorylation Assay.** Stably transduced human embryonic kidney-293 cells overexpressing human insulin receptor (hIR) isoform A (hIR-A) or hIR-B containing a C-terminal C9 epitope (Hodges et al., 1988), or human IGF-1 receptor (hIGF-1R). The scintillation proximity assay uses either 3-[125I]iodotyrosyl-A14)-insulin or [125I]IGF-1 and is configured as previously published (Kohn et al., 2007). Receptor-bound radioactivity was quantified using a MicroBeta TriLux scintillation counter (PerkinElmer, Waltham, MA).

**Binding to Human Insulin Receptor and Human Insulin-Like Growth Factor 1 Receptor.** The inhibitory binding constant ($K_{i}$) was determined using crude plasma membranes prepared from stably transduced human embryonic kidney-293 cells overexpressing human insulin receptor (hIR) isoform A (hIR-A), hIR isoform B (hIR-B) containing a C-terminal C9 epitope (Hodges et al., 1988), or human IGF-1 receptor (hIGF-1R). The scintillation proximity assay uses either 3-[125I]iodotyrosyl-A14)-insulin or [125I]IGF-1 and is configured as previously published (Kohn et al., 2007). Receptor-bound radioactivity was quantified using a MicroBeta TriLux scintillation counter (PerkinElmer, Waltham, MA).

**Metabolic Potential Assay.** Murine 3T3-L1 fibroblasts (CL-173; American Type Culture Collection, Manassas, VA; American Type Culture Collection, 2011) were differentiated into adipocytes as described by the supplier (by using modified concentrations of 5 µg/ml insulin and 0.5 µM dexamethasone). Differentiated murine 3T3-L1 adipocytes were serum-starved overnight at 37°C. Cells were treated with test samples in Krebs-Ringer buffer supplemented with 10 µM glucose and 0.05% BSA in the presence of 0.1 µCi/well D-(U-14C)-glucose (PerkinElmer, Waltham, MA). After 4 hours, the adipocytes were rinsed and lysed in 0.05 ml of 0.5% Triton X-100 and shaken at
600 rpm for 5 minutes. The newly synthesized triglycerides were extracted by adding 0.05 ml of sec-butanol and 0.1 ml of MicroScint-E (PerkinElmer, Waltham, MA), followed by overnight incubation. The radioactivity incorporated into the triglycerides was quantified using a MicroBeta TriLux scintillation counter and expressed as counts per minute. Values were normalized by the response of a maximally efficacious dose of BHI (100 nM).

Mitogenic Potential Assay. The human osteosarcoma cell line, SAOS-2, (HTB-85; American Type Culture Collection) was plated at 40,000 cells/well in CytoStar T microplates (PerkinElmer) for 72 hours in growth medium (see Supplemental Material). The following morning, cells were rinsed and incubated with serum-free growth medium supplemented with 0.1% BSA for 6 hours before the test samples were added. After 20 hours, 1 μCi/well methyl-[3H]thymidine (PerkinElmer) was added, and the amount of radioactivity incorporated into the cellular DNA was determined 4 hours later using a MicroBeta TriLux scintillation counter and expressed as counts per minute. Values were normalized by the response to a maximally efficacious dose of BHI (100 nM).

hIR Dephosphorylation Assay. To follow the dephosphorylation kinetics of hIR, the same cell lines and protocol used in the hIR phosphorylation assay were followed, except that the cells were stimulated for 30 minutes with maximally efficacious doses of the insulin analogs (100 nM insulin lispro, 100 nM insulin AspB10, 1000 nM insulin glargine, and 1000 nM BIL). Dephosphorylation was started after two media exchanges into serum-free growth medium supplemented with 0.1% BSA. At defined time points, cells were rinsed with ice-cold PBS and lysed with NP40 lysis buffer, and enzyme-linked immunosorbent assay analysis was performed as described earlier. Values were normalized as a percentage of the mean starting (pre-wash) values for all control wells using a maximally efficacious dose of insulin (100 nM).

Data Analysis for In Vitro Activity. IC50 or EC50 values were determined from a four-parameter logistic nonlinear regression analysis (see Supplemental Material). Functional assay results were reported as EC50 values. All results are reported as the geometric mean ± S.E.M.

Analysis of the dephosphorylation results was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC), using a mixed model including fixed treatment group, time, and treatment group–by–time interaction effects and random plate effects. Treatments were compared at each time point by model-based t tests.

Results

PK and PD Profiles in STZ-Treated Diabetic Rats. BIL and insulin lispro were compared for PK (Fig. 1A) and PD (Fig. 1, B and C) characteristics in rats rendered diabetic by treatment with STZ. BIL exhibited a clear, protracted time-action profile relative to insulin lispro, and the response was dose-dependent, as exemplified in the PK and PD profiles. In fact, the insulin lispro PK profile was nearly complete at the first time point recorded for BIL (Fig. 1A). Analysis of the PK data reveals that BIL demonstrated a 13-fold decrease in clearance and a 10-fold increase in area under the concentration-time curve, as well as a substantial increase (24.5-fold) in the time to maximum concentration, suggesting that the rate of absorption as well as clearance was reduced relative to insulin lispro (Table 1).

Binding Affinity for hIR and hIGF-1R Selectivity. All insulin test articles demonstrated comparable Ki for hIR-A, the ubiquitously expressed isoform, and hIR-B, the isoform predominantly expressed in the liver (Table 2). Unlike the insulins, hIGF-1 showed an approximately 15-fold greater binding affinity (lower Ki value) for hIR-A than for hIR-B.

Compared with insulin lispro, the binding affinities of insulin detemir for hIR-A and hIR-B were reduced approximately 8-fold and 7-fold, respectively, whereas the binding affinities of BIL were reduced approximately 15-fold and 17-fold for hIR-A and hIR-B, respectively (see Supplemental Fig. 1, A and B for binding curves). Results in Table 2 show that each of the insulin test samples exhibited lower binding affinity for hIGF-1R than for hIR.
Compared with insulin lispro, BIL showed an 86-fold reduced binding affinity for hIGF-1R (see Supplemental Fig. 1C for binding curves). Insulin lispro and BIL were 238-fold and 1351-fold more selective for hIR-A binding than for hIGF-1R binding, respectively, as assessed by the ratio of the $K_i$ values for each receptor. Overall, the hIR-A selectivity of BIL was approximately 6-fold, 37-fold, and 9-fold greater than that of insulin lispro, insulin glargine, and insulin detemir, respectively. Since equivalent binding to hIR-A and hIR-B was observed for all insulin molecules tested, only the selectivity ratios for hIR-A are shown in Table 2.

To place the data for in vitro binding to hIR-A and hIGF-1R in clinical context, the competitive displacement profiles of BIL for the cognate ligands were overlaid with the steady-state plasma concentration range observed in a clinical trial in type 2 diabetes mellitus (T2DM) patients (Sinha et al., 2014b) (Fig. 2). In the 14-day clinical trial, patients achieved steady-state levels of BIL; daily doses of BIL ranged from 0.33 to 1.0 U/kg. The shaded box within Fig. 2 delineates the lowest (3.2 nM) and the highest (16.0 nM) plasma concentrations of BIL observed in the clinical trial. This range of plasma concentrations encompasses the steady-state levels achieved in clinical testing in T1DM (3.2 nM) and T2DM (4.3 nM) patients (Henry et al., 2014). Because the range of clinical exposures for BIL spanned the binding affinity for hIR-A, BIL would be expected to engage the receptor. Given the lower binding affinity for hIGF-1R, even at the highest exposures, BIL would not be expected to engage hIGF-1R.

**Functional Activity by hIR Autophosphorylation and De Novo Lipogenesis in Differentiated Mouse 3T3-L1 Adipocytes.** As expected from the reduced binding affinities, BIL also showed approximately 10-fold lower functional activity for stimulating tyrosine autophosphorylation of both hIR-A and hIR-B compared to that of insulin lispro (Table 3). BIL induced a maximal level of phosphorylation similar to that of insulin lispro (Supplemental Fig. 2, A and B), which suggests that BIL is a full agonist for both hIR-A and hIR-B autophosphorylation. All other test samples also reached maximal responses similar to that of insulin lispro (data not shown).

To link the functional activation of hIR with an intrinsic metabolic response, insulin-stimulated de novo lipogenesis of triglycerides from $[^{14}C]$-labeled glucose was measured by using mouse 3T3-L1 adipocytes (Table 3). BIL achieved a maximal response comparable to that of insulin lispro (Supplemental Fig. 2C), as did the other insulin test samples (data not shown). The relative lipogenic potency ($EC_{50}$) of BIL was approximately 10-fold lower than the potency observed for insulin lispro, which correlates with the observed lower hIR binding affinity and hIR autophosphorylation potency. The comparable lipogenic potencies of BIL were 238-fold and 1351-fold more selective for hIR-A binding than for hIGF-1R, respectively, as assessed by the ratio of the $K_i$ values for each receptor. Overall, the hIR-A selectivity of BIL was approximately 6-fold, 37-fold, and 9-fold greater than that of insulin lispro, insulin glargine, and insulin detemir, respectively. Since equivalent binding to hIR-A and hIR-B was observed for all insulin molecules tested, only the selectivity ratios for hIR-A are shown in Table 2.

<table>
<thead>
<tr>
<th>Test Sample</th>
<th>$\tau_{max}$</th>
<th>AUC_{0-1}</th>
<th>CL/F</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>h</td>
<td>nM*h</td>
<td>h/l/kg</td>
</tr>
<tr>
<td>Insulin lispro</td>
<td>0.4 (0.2)</td>
<td>25 (15)</td>
<td>3.0 (1.8)</td>
</tr>
<tr>
<td>BIL</td>
<td>9.8 (1.1)</td>
<td>255 (37)</td>
<td>0.23 (0.04)</td>
</tr>
<tr>
<td>BIL/insulin lispro, mean</td>
<td>24.5</td>
<td>10.2</td>
<td>0.08</td>
</tr>
</tbody>
</table>

AUC_{0-1}, area under the concentration-time curve from time zero to infinity; CL/F, apparent clearance; $\tau_{max}$, maximum concentration.

*Values for insulin lispro and BIL represent the mean (S.D.) across multiple studies that used similar dose levels (approximately 50 nmol/kg).
Mitogenic Potential. The mitogenic potentials of BIL and the comparator insulins were evaluated by using the human osteosarcoma cell line SAOS-2, a cell line that expresses 10 times more hIGF-1R than hIR (Kurtzhals et al., 2000) and is commonly used for determining the mitogenic potential of insulin analogs (Kurtzhals et al., 2000; Liefvdahl and Arnqvist, 2008). As expected, IGF-1 was more potent than insulin lispro for increasing DNA synthesis, as measured by methyl-[3H]thymidine incorporation (Table 4). Insulin glargine and insulin AspB10 had the greatest mitogenic potencies of the insulins tested, which correlated with their observed higher binding affinities for hIGF-1R and was consistent with previously reported results (Kurtzhals et al., 2000). BIL showed lower mitogenic potential than insulin lispro (by 25-fold) and insulin glargine (by 49-fold). The presence of BSA in this assay contributes to an underestimation of the mitogenic potential of insulin detemir because of albumin binding, and therefore prevents a conclusive comparison with BIL.

TABLE 3
Reduction of the functional activity of BIL for hIR-A and hIR-B receptor autophosphorylation and de novo lipogenesis in mouse 3T3-L1 adipocytes

<table>
<thead>
<tr>
<th>Test Sample</th>
<th>hIR-A Phosphorylation, $EC_{50}$ (S.E.M., Number of Replicates)</th>
<th>hIR-B Phosphorylation, $EC_{50}$ (S.E.M., Number of Replicates)</th>
<th>De Novo Lipogenesis, $EC_{50}$ (S.E.M., Number of Replicates)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIL</td>
<td>$35.4 \pm 1.5, 7^{***}$</td>
<td>$29.4 \pm 3.8, 7$</td>
<td>$21.4 \pm 5.8, 3$</td>
</tr>
<tr>
<td>Insulin lispro</td>
<td>$3.69 \pm 0.68, 12^{***}$</td>
<td>$2.66 \pm 0.36, 11^{***}$</td>
<td>$2.56 \pm 0.13, 4^{***}$</td>
</tr>
<tr>
<td>BHI</td>
<td>$4.42 \pm 0.31, 79^{***}$</td>
<td>$3.06 \pm 0.06, 58^{***}$</td>
<td>$2.70 \pm 0.39, 22^{***}$</td>
</tr>
<tr>
<td>Insulin AspB10</td>
<td>$1.38 \pm 0.57, 10^{***}$</td>
<td>$1.00 \pm 0.31, 8^{***}$</td>
<td>$0.77 \pm 0.09, 7^{***}$</td>
</tr>
<tr>
<td>Insulin glargine</td>
<td>$5.24 \pm 0.33, 16^{***}$</td>
<td>$3.32 \pm 0.20, 16^{***}$</td>
<td>$8.30 \pm 0.10, 12^{***}$</td>
</tr>
<tr>
<td>Insulin detemir</td>
<td>$344 \pm 137, 4^{***}$</td>
<td>$313 \pm 188, 3^{***}$</td>
<td>ND</td>
</tr>
<tr>
<td>IGF-1</td>
<td>$143 \pm 39, 5^{***}$</td>
<td>$&gt;20,000 (n=2)^{***}$</td>
<td>$1.99 \pm 0.72, 8^{***}$</td>
</tr>
</tbody>
</table>

ND, not determined.

*Means are reported as the geometric mean using the log-transformed $EC_{50}$ potency values (S.E.M., number of replicates) for each test material using log10 transformation of each value.

**Potency values, $EC_{50}$ reported for insulin detemir may not reflect the actual potency because of the presence of serum albumin in the assay buffers.

*P < 0.01; **P < 0.001 by Dunnett's analysis in $EC_{50}$ relative to BIL.

Discussion

Compared with BHI and the analogs lispro, detemir, and glargine, the unique in vitro and in vivo activity profiles emerging for BIL support the therapeutic usefulness of this novel basal insulin molecule. BIL exhibited stronger selectivity for hIR than for hIGF-1R and showed full agonistic activity in all of the functional in vitro assays (albeit with weaker receptor binding affinity and, consequently, higher $EC_{50}$ values), lower mitogenic potential, and more rapid dephosphorylation of hIR following activation by BIL.

The in vivo PK and PD characterization of BIL revealed a markedly delayed $T_{\text{max}}$ after s.c. injection, an increased area under the concentration-time curve, and a prolonged duration of action compared with insulin lispro in the STZ-treated diabetic rat. PEGylation of insulin lispro delays or alters s.c. absorption, reduces renal clearance (Hansen et al., 2012b), and probably alters receptor-mediated clearance via weaker binding affinity (Flier et al., 1982). It is possible that the slower absorption of BIL, because of its larger hydrodynamic size, may reflect a shift from a predominantly more rapid capillary absorption (Charman et al., 2001) to a slower lymphatic absorption. Moreover, the therapeutic advantages of BIL over insulin glargine observed in the phase 2 clinical trials (Bergenstal et al., 2012; Rosenstock et al., 2013) may be attributable, in part, to the increased hepato-preferential activity (Henry et al., 2014; Moore et al., 2014). These advantages include weight loss, reduced mealtime insulin dosage, reduced nocturnal hypoglycemia, and improved glycemic control in patients with type 1 diabetes (Rosenstock et al., 2013), and weight loss, reduced nocturnal hypoglycemia, and reduced intraday glucose variability in patients with type 2 diabetes (Bergenstal et al., 2012).

The hIR binding affinity of BIL, although significantly lower than that of insulin lispro and BHI, was still comparable with the binding affinity observed for insulin detemir. The higher concentrations of BIL needed to activate the hIR in the current preclinical studies have also been observed in phase 1 dose-response studies that achieved steady-state plasma levels ranging from 3.2 to 16 nM (Sinha et al., 2014a), consistent with the in vitro $K_i$ (hIR) for BIL of approximately 5 nM. This lower binding affinity also provides a means to modulate receptor-mediated clearance of BIL with protracted PK profiles. Thus, the weaker binding affinity to hIGF-1R for BIL relative to BHI and insulin lispro coupled with the comparatively lower
mitogenic potential for BIL in vitro suggests that BIL will exhibit an overall mitogenic safety profile equal to or better than those of other insulin analogs. Moreover, as shown in Fig. 2, the relationship between the observed plasma concentrations in T2DM patients treated with BIL and the $K_i$ values required for BIL to displace either human insulin from hIR or hIGF-1 from the hIGF-1R suggests the concentrations would be sufficient to engage the hIR, but incapable of competing with hIGF-1 for the hIGF-1R.

Data generated with insulin AspB10 suggest that activity through the hIR and hIGF-1R can stimulate cell proliferation at appropriate concentrations; thus, mitogenicity can be a risk with any insulin therapy. During chronic administration in rats, insulin AspB10 induced mammary tumors (Jorgensen et al., 1992). This tumorigenic action is hypothesized to involve both the activation of the IGF-1R and the prolongation of the residence time on the insulin receptor (Jorgensen et al., 1992; Hansen et al., 1996, 2011, 2012a). The hIR dephosphorylation assay performed in this research is in agreement with previous studies, i.e., insulin AspB10 showed a markedly longer duration of hIR phosphorylation, whereas insulin lispro, insulin glargine, and BIL all showed significantly faster rates of hIR dephosphorylation, with BIL displaying a more rapid rate of dephosphorylation. This rapid dephosphorylation, coupled with increased receptor selectivity for the hIR, supports a mitogenicity profile for BIL that is equal to or better than that of BHI or insulin lispro.

In conclusion, BIL demonstrated in vivo PK and PD properties and in vitro metabolic and mitogenic properties that are appropriate for a once-daily basal insulin analog. The longer PD profile, which is related to delayed absorption and altered clearance, seems suitable for a basal insulin. Thus, BIL provides a mechanism to alter absorption, clearance, distribution, and, consequently, activity profile, while maintaining full agonist receptor signaling properties. The in vitro metabolic and mitogenic characteristics of BIL were similar or improved compared to those of BHI, insulin lispro, and insulin glargine, all well-established therapeutic agents, with the added benefit of improved receptor selectivity against hIGF-1R. These results provide additional support for a favorable mitogenic profile, with an effective once-daily basal insulin therapy as demonstrated in clinical studies (Bergenstal et al., 2012; Rosenstock et al., 2013).

**Acknowledgments**

The authors acknowledge the contributions of the following Lilly Research Laboratories employees: Liyun Ding (assay assistance), Bernice Ellis (PK support), Andrea Sperry (ADME support), and Amy Ford (in vivo studies). The authors acknowledge the editorial assistance of Robert Panek of INC Research (Raleigh, NC).

**TABLE 4**

The reduced mitogenic potential of BIL in the human SAOS-1 osteosarcoma cell line

<table>
<thead>
<tr>
<th>Insulin Test Sample</th>
<th>SAOS-2 Mitogenesis, EC50 (S.E.M., Number of Replicates)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIL</td>
<td>29.4 (8.1, 4)***</td>
</tr>
<tr>
<td>Insulin lispro</td>
<td>1.18 (0.24, 8)***</td>
</tr>
<tr>
<td>BHI</td>
<td>2.69 (0.63, 30)***</td>
</tr>
<tr>
<td>Insulin AspB10</td>
<td>0.37 (0.06, 22)***</td>
</tr>
<tr>
<td>Insulin glargine</td>
<td>0.61 (0.002, 17)***</td>
</tr>
<tr>
<td>Insulin detemir b</td>
<td>17.3 (3.7, 3)***</td>
</tr>
<tr>
<td>IGF-1</td>
<td>0.04 (0.01, 3)***</td>
</tr>
</tbody>
</table>

*Means are reported as the geometric mean using the log-transformed potency values (S.E.M., number of replicates).

Potency values, EC50, reported for detemir may not reflect the actual potency because of the presence of serum albumin in the assay buffers.

***$P < 0.001$ by Dunnett’s analysis in EC50 relative to BIL.


Li, Ruan, Kahl.


Sanofi-Aventis (2013) Lantus (insulin glargine [rDNA origin] injection) prescribing information, Sanofi-Aventis, Bridgewater, NJ.


Address correspondence to: Dr. John M. Beals, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: beals_john_m@lilly.com